2019
DOI: 10.1002/ana.25493
|View full text |Cite
|
Sign up to set email alerts
|

Cell therapy for ischemic stroke: Are differences in preclinical and clinical study design responsible for the translational loss of efficacy?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
40
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
2
1

Relationship

3
6

Authors

Journals

citations
Cited by 57 publications
(44 citation statements)
references
References 61 publications
0
40
0
Order By: Relevance
“…On the other hand, previous has demonstrated that cryopreservation of cells would reduce the efficacy [29]. Additionally, ageing and senescence effects due to cryopreservation [30] that could also contribute to negative or neutral results [31]. Accordingly, when hemopoietic-derived stem cell therapy is taken into consideration for acute IS patients, minimal manipulation (i.e., cells without cultivation) method to collect the circulatory-derived/bone marrowderived autologous CD34+ cells would be more practical and suitable for the IS patients in our daily clinical practice.…”
Section: Discussionmentioning
confidence: 99%
“…On the other hand, previous has demonstrated that cryopreservation of cells would reduce the efficacy [29]. Additionally, ageing and senescence effects due to cryopreservation [30] that could also contribute to negative or neutral results [31]. Accordingly, when hemopoietic-derived stem cell therapy is taken into consideration for acute IS patients, minimal manipulation (i.e., cells without cultivation) method to collect the circulatory-derived/bone marrowderived autologous CD34+ cells would be more practical and suitable for the IS patients in our daily clinical practice.…”
Section: Discussionmentioning
confidence: 99%
“…Most types of cells are impaired by the process of freezing and thawing. Indeed, clinical islet transplantation is performed with freshly isolated islets and recent meta-analysis reported the inferiority of cryopreserved cells in the therapeutic efficacy of cell therapy for ischemic stroke [22]. Hepatocytes also easily lose their viability after freezing and thawing [23].…”
Section: Discussionmentioning
confidence: 99%
“…There are several routes currently available for cell transplantation, including intraparenchymal, intravenous, intra-arterial, and intrathecal injections. Although the optimal cell transplantation route has not been determined, most clinical studies have applied intraparenchymal or intravenous routes of transplantation [15]. The intraparenchymal route delivers a sufficient number of cells into the desired brain lesion, having a strong advantage over the intravenous route, by which only a small number of cells can be delivered [2], most of which are trapped in the lung and spleen.…”
Section: Discussionmentioning
confidence: 99%
“…The intravenous delivery method is still efficient because neurotrophic factors are released from the cells and are critical in immunomodulation and anti-inflammation, especially at the acute stage of disease. However, when considering the subacute and chronic stages, delivering cells to the damaged area needs to be important to reorganize the damaged neurons, and recent systemic analyses have reported that intraparenchymal cell transplantation is superior to the intravenous one from an efficacy point of view, as demonstrated in both the preclinical and clinical trials [15]. Nevertheless, the intraparenchymal transplantation has a serious burden, which is that the transplantation cannula can induce intraparenchymal hemorrhage, and occlusion of the cannula may occur.…”
Section: Discussionmentioning
confidence: 99%